September 25, 2024 – The Center for Molecular Interactions in Cancer (CMIC) COBRE, (Award P20 GM152281) hosted the first full-day advisory committee (AC) meeting in the Betsy Blass Board Room on September 25, 2024. The COBRE PI, Dr. Robert Eoff kicked off the meeting with an update of recent CMIC activities, followed by research presentations from Project Leaders Dr. Mohammad Rahman, Dr. Joonas Jamsen, Dr. Sayem Miah and Dr. Katie Ryan. The CMIC Core Directors, Dr. Eric Enemark (Structural Biology) and Dr. Kevin Raney (Biomolecular Interactions) also provided updates for core facilities, instrumentation and ongoing projects. The CMIC faculty and staff are grateful for the support from the AC members for their insights and suggestions, and to the Research Program Director Veronica Overton for making the gathering such a great success.
CMIC News
Research Milestone for Kevin Raney
September 1, 2024 – Congratulations to Dr. Kevin Raney, Ph.D., Professor and Chair of the Department of Biochemistry and Molecular Biology and the Biomolecular Interactions Core Director for the Center for Molecular Interactions in Cancer. During his scientific career, he has now published more than 100 scientific papers that are indexed by PubMed at the National Library of Medicine.
CMIC Represented at the National IDeA Symposium
June 16, 2024: The Arkansas IDeA programs, including the CMIC, were well represented at the 9th Biennial National IDeA Symposium of Biomedical Research Excellence (NISBRE). The national conference was held in Washington, DC on June 16-19 and included researchers from across the nation. Drs. Enemark, Eoff, and Raney attended and had a great time interacting with other IDeA scientists and NIH staff. CMIC RPL, Dr. Katie Ryan also attended and presented a poster detailing her latest findings detailing the involvement of the Rnd3 GTPase in lung cancer.
Recent Publication for the CMIC
May 15, 2024: Congratulations to Dr. Katie Ryan on her recent publication in Biorganic & Medicinal Chemistry entitled “Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors” . In this study, Dr. Ryan and her collaborator, Dr. Brendan Frett (an RPL on Dr. Boerma’s COBRE), developed dual RET/TRK inhibitors with potential applications targeting aberrant signaling mechanisms of multiple, treatment resistant cancers. This was the first publication to cite the CMIC award P20 GM152281. So, a big “THANK YOU!!!” to Dr. Ryan and her team for citing our COBRE.